Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
about
Invasive mold infections in solid organ transplant recipientsComparison of echinocandin antifungalsSafety and Efficacy of Anidulafungin for Fungal Infection in Patients With Liver Dysfunction or Multiorgan FailureQuantitative analysis of the antifungal drug anidulafungin by LC-online SPE-MS/MS in human plasma.Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.Limited-sampling strategies for anidulafungin in critically ill patients.Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Echinocandins: role in antifungal therapy, 2005.Emerging echinocandins for treatment of invasive fungal infections.The safety of anidulafungin.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Anidulafungin: a new echinocandin for candidal infections.The echinocandins.Anidulafungin--state of affairs from a clinical perspective.A comparative evaluation of properties and clinical efficacy of the echinocandins.Functional characterization of tlmK unveiling unstable carbinolamide intermediates in the tallysomycin biosynthetic pathway.Antifungal agents--clinical pharmacokinetics and drug interactions.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Anidulafungin: an evidence-based review of its use in invasive fungal infections.Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?Anidulafungin: when and how? The clinician's view.The Eagle-like effect of echinocandins: what's in a name?Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.Impact of special patient populations on the pharmacokinetics of echinocandins.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results.[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].Interactions between anti-infective agents and immunosuppressants in solid organ transplantation.Aspergillosis in solid organ transplantation.Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.Anidulafungin and its role in candida infectionsIn vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.Safety of anidulafungin in solid organ transplant recipientsPharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins
P2860
Q26823811-19F5DC0A-169A-44D8-BB12-938D4CF8ED68Q28273738-267F88E3-67CF-4039-A09C-F99CC47487DAQ33629353-07A07AFC-5B33-4278-A63E-228E6CB35581Q34054746-5A90C7F3-C10F-4D6C-9A1D-36AE8DFBA6A7Q34352100-505169F0-CE07-4FE2-80C7-AA6700933C67Q35105939-602130E6-8F25-4919-BAC4-BF02E94ECB6AQ35959489-A4DA6B03-4D6E-4969-B0EC-AD2F1FCE2FE7Q36222035-E08E4D21-9C30-4D6D-897A-DDCD8FEE98E4Q36458402-B0474EB4-FB54-48F6-A033-0AD804108974Q36624970-FCCEFBE0-768C-4F1D-B9BC-FF001B8D3DCCQ36626518-EAB61BA7-2691-4875-98B4-C18BC5E943BFQ36723788-1083FE9E-1AF1-4EF0-917F-6E14CDB35D8BQ36742397-548AA94A-74D8-4077-8095-9B04BFBAC8FCQ36774257-4E3BE3EA-93B1-4C33-8DD3-DD63808D473BQ36895839-0019CC12-142F-4100-800C-59D3EA2F0F39Q37136721-0F142011-F8F4-40F4-8F49-5096F297AFF2Q37159568-EA5D9481-B7B1-4E7F-9252-E37AF3EB09B1Q37785979-CBE3F762-30D1-476B-95BC-DD6B1DD5CD1CQ37827345-5C244066-8667-4336-82F4-A59C1485D827Q37854724-6AA3990D-EA86-4C4B-92D2-771D516B1C0BQ37888751-A0D1008A-3153-44F1-80C7-66F0C8D31E82Q38153458-B7ADDB32-8A93-4733-8E4D-63128F1457EDQ38284468-C51E23DF-0F47-403A-9590-49C9B1E29031Q38419657-C8D6DC33-DF85-4937-80B5-1F47046626BEQ38462784-F4BE47A6-9475-4482-9240-FFF494EF94F0Q38681635-B4692B9E-13D4-461E-9C4D-D60A30152D66Q39077602-0B3AD11C-CC8B-4433-92EC-D72DD32B185FQ40225550-F4FB86D0-64B2-46D4-BA5F-11EC7D1A214FQ40488737-19E5B24C-C650-4F88-AE3F-419B9C06D87CQ42272268-578E2BC9-0072-459C-9F5A-4AA664878F51Q42272291-D93E910F-71E7-430F-AFDF-54B8A97301C9Q42612968-41DE2D8A-7BF4-43F2-B3C8-F6F332D638C6Q42731827-8CF64790-14D0-4C42-BC4D-7044D03B9098Q43169846-072CC741-2C22-41D3-87BF-A6EF3DEDBC3AQ46807629-D4664D43-34F1-46FA-8ADB-62BB1E25D440Q54957028-ABF2010F-A9ED-4501-BE2A-D3FB2C18A2EFQ57569012-EBA8537D-63E5-4768-9760-63F165895056Q57746174-C6E38830-326C-4EB9-972B-7F948529B1F0
P2860
Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Assessment of the safety and p ...... dministered with cyclosporine.
@en
Assessment of the safety and p ...... dministered with cyclosporine.
@nl
type
label
Assessment of the safety and p ...... dministered with cyclosporine.
@en
Assessment of the safety and p ...... dministered with cyclosporine.
@nl
prefLabel
Assessment of the safety and p ...... dministered with cyclosporine.
@en
Assessment of the safety and p ...... dministered with cyclosporine.
@nl
P2093
P2860
P356
P1476
Assessment of the safety and p ...... dministered with cyclosporine.
@en
P2093
David Krause
Irving E Weston
James A Dowell
Martin Stogniew
Timothy Henkel
P2860
P304
P356
10.1177/0091270004270146
P577
2005-02-01T00:00:00Z